Fosamax Geriatric (65+) Dosing: What Every Older Patient and Clinician Needs to Know

What Is the Correct Alendronate Dose for Adults Aged 65 and Older?

The approved dose of alendronate for treatment of postmenopausal osteoporosis and osteoporosis in men does not change based on age alone. Adults 65 and older receive the same labeled dose as younger adults: 70 mg orally once weekly or 10 mg orally once daily. The FDA-approved prescribing information for alendronate sodium confirms that no dosage adjustment is warranted for age, provided renal function is adequate [1].

The once-weekly 70 mg regimen became standard after a randomized, double-blind, 12-month trial (N=1,258) demonstrated equivalent bone mineral density (BMD) gains at the lumbar spine and hip compared with the 10 mg daily regimen, with a similar gastrointestinal tolerability profile [2]. For most geriatric patients, the once-weekly schedule improves adherence substantially. A 12-month observational cohort of Medicare beneficiaries (N=8,734) found that once-weekly bisphosphonate dosing was associated with a 32% higher medication possession ratio compared with daily dosing in adults over age 65 [3].

Prevention of osteoporosis in postmenopausal women with low bone mass (T-score between -1.0 and -2.5) uses a lower dose: 35 mg once weekly or 5 mg once daily. Clinicians should confirm the indication before prescribing, because treatment and prevention doses differ.

Alendronate is available as a 70 mg tablet, a 70 mg effervescent tablet dissolved in water, and a 70 mg/75 mL oral solution. All three formulations carry the same bioavailability requirements and administration instructions [1].

Why Renal Function Is the Most Important Dosing Modifier in Older Adults

Alendronate is eliminated unchanged by the kidney. Age-related decline in glomerular filtration rate makes renal assessment the central safety check before prescribing in patients aged 65 and older. The FDA label contraindicates alendronate when creatinine clearance is below 35 mL/min [1].

Renal function declines at roughly 0.75 to 1.0 mL/min per year after age 40 in the general population, meaning a 70-year-old patient may have a CrCl well below their younger baseline even with a normal serum creatinine [4]. Serum creatinine alone underestimates this decline because lean muscle mass decreases with age, reducing creatinine production. The Cockcroft-Gault equation using actual body weight, or the CKD-EPI equation, should be used to calculate estimated CrCl before initiating therapy and at least annually thereafter [5].

In the CrCl range of 35 to 60 mL/min (CKD stages G3a-G3b), alendronate may be used with caution. The American Association of Clinical Endocrinology (AACE) 2020 guidelines note that "bisphosphonates should be used cautiously in patients with CKD stage 3, with periodic monitoring of renal function and calcium metabolism" [6]. Below CrCl 35 mL/min, accumulation in bone increases substantially, and the risk of adynamic bone disease and hypocalcemia rises. At that threshold, alternative agents (denosumab, romosozumab, or teriparatide) become the preferred options.

Calcium and vitamin D status must be corrected before starting alendronate. Hypocalcemia is a contraindication. The National Osteoporosis Foundation recommends 1 to 200 mg/day total dietary and supplemental calcium plus 800, 1 to 000 IU vitamin D3 daily for adults over 50 [7].

The Fracture Intervention Trial: The Key Evidence Base in Older Women

The Fracture Intervention Trial (FIT), published in JAMA in 1998, remains the foundational efficacy study for alendronate in postmenopausal women with osteoporosis. The trial enrolled 2,027 women aged 55, 81 with femoral neck BMD T-scores of -1.6 or below and at least one pre-existing vertebral fracture [8]. Over three years, alendronate reduced the risk of new radiographic vertebral fractures by 47% (relative risk 0.53 to 95% CI 0.41, 0.68, P<0.001) compared with placebo. Hip fracture risk fell by 51% (RR 0.49 to 95% CI 0.23, 0.99) [8].

A companion FIT arm (N=4,432 women without pre-existing vertebral fracture) showed that alendronate reduced clinical fractures in women with femoral neck T-scores at or below -2.5, but the reduction in the overall arm was not statistically significant for vertebral fractures alone, underscoring that baseline fracture risk drives the magnitude of benefit [9].

Mean age of participants across both FIT arms was approximately 68 years, making the trial directly applicable to the geriatric prescribing decision. The trial's open-label extension and subsequent follow-up data support continued efficacy for up to ten years of therapy [10].

A practical three-step framework for geriatric alendronate initiation:

1. Confirm the indication using FRAX (10-year fracture probability) plus DXA T-score. The National Bone Health Alliance threshold for pharmacotherapy is a 10-year hip fracture probability of 3% or greater, or major osteoporotic fracture probability of 20% or greater [11].
2. Screen for contraindications: CrCl <35 mL/min, esophageal abnormalities, inability to sit or stand upright for 30 minutes, hypocalcemia, and allergy to any bisphosphonate.
3. Check for high-risk drug interactions and calculate falls risk using the STEADI algorithm before the first prescription is written.

Administration Rules That Are Non-Negotiable in Geriatric Patients

Alendronate has poor oral bioavailability (roughly 0.7%) that drops to near zero if taken incorrectly. The FDA label requires the tablet be swallowed with a full 240 mL (8 fl oz) of plain water only, in the morning, at least 30 minutes before any food, drink, or other medication, with the patient remaining upright (sitting or standing) for at least 30 minutes after ingestion [1].

These rules matter more in older adults for two reasons. First, esophageal motility decreases with age, slowing transit time and raising the risk of esophageal mucosal contact. Esophagitis, esophageal ulcer, and, rarely, esophageal stricture have been reported [12]. Patients with a history of Barrett's esophagus, achalasia, or severe dysmotility should not receive alendronate. Second, many older adults take morning medications at breakfast. Alendronate must be physically separated from all other oral medications by at least 30 minutes; calcium supplements and antacids should be separated by at least two hours because divalent cations bind alendronate in the gut and reduce absorption sharply [1].

For patients who cannot reliably follow the 30-minute fasting window due to cognitive impairment or care-facility routines, the effervescent tablet formulation or the oral solution may improve compliance, though both carry identical administration requirements [1].

Drug-Drug and Drug-Disease Interactions in the Geriatric Population

Older adults carry a median of five to seven chronic prescription medications. This polypharmacy backdrop creates meaningful interaction risks that clinicians must screen at each visit.

NSAIDs and aspirin are among the most common interacting agents. Both independently irritate the esophageal and gastric mucosa, and concurrent use with alendronate approximately doubles the odds of upper GI adverse events compared with alendronate alone [13]. A case-control study using the UK General Practice Research Database found that current NSAID use in bisphosphonate-treated patients was associated with an odds ratio of 2.2 (95% CI 1.5, 3.1) for upper GI hospitalization [13]. For geriatric patients requiring chronic NSAID therapy, clinicians should weigh whether denosumab or another non-oral agent represents a safer route.

Proton pump inhibitors (PPIs) do not reduce alendronate absorption. However, the concurrent use of PPIs with bisphosphonates warrants monitoring because long-term PPI use is independently associated with reduced bone mineral density, though the clinical significance of this interaction on fracture outcomes remains debated [14].

Loop diuretics (furosemide, torsemide) used commonly in older adults for heart failure increase urinary calcium excretion. Patients on loop diuretics who start alendronate should have serum calcium and 25-OH vitamin D checked within four to six weeks of initiation, with calcium/vitamin D supplementation optimized first [7].

Glucocorticoids accelerate bone loss by suppressing osteoblast function and increasing osteoclast lifespan. Alendronate 5 to 10 mg daily or 35 to 70 mg weekly is used specifically to prevent and treat glucocorticoid-induced osteoporosis (GIOP). The American College of Rheumatology 2022 GIOP guideline recommends bisphosphonate therapy for patients aged 40 and older who are expected to receive 2.5 mg/day or more of prednisone for three or more months [15].

Monitoring Parameters After Initiation in Older Adults

Baseline and follow-up monitoring should follow a structured schedule. Before prescribing, obtain DXA of the lumbar spine and hip, serum creatinine with estimated CrCl, serum calcium, 25-OH vitamin D, and complete blood count if clinically indicated. The Endocrine Society's 2019 osteoporosis guideline recommends DXA monitoring every one to two years after initiating therapy until BMD is stable, then every two to five years depending on baseline risk [16].

Serum creatinine and calculated CrCl should be checked annually because renal function can deteriorate between prescriptions. If CrCl drops to below 35 mL/min at any point, alendronate should be stopped and an alternative considered.

Bone turnover markers (BTMs) such as serum C-terminal telopeptide (CTX) and procollagen type 1 N-terminal propeptide (P1NP) offer a window into treatment response within three to six months. The International Osteoporosis Foundation recommends a 25 to 35% decrease in CTX from baseline as evidence of adequate antiresorptive effect [17]. If CTX does not fall adequately despite confirmed adherence, assess for secondary causes of bone loss (malabsorption, hyperparathyroidism, multiple myeloma) or consider switching to a more potent antiresorptive agent such as zoledronic acid 5 mg IV annually.

Osteonecrosis of the Jaw and Atypical Femur Fractures: Absolute Risk in Context

Two rare but serious adverse effects receive disproportionate media attention and sometimes deter clinicians from prescribing alendronate in older adults who stand to benefit substantially.

Osteonecrosis of the jaw (ONJ) in patients taking oral bisphosphonates for osteoporosis occurs at an estimated rate of 1 in 10,000 to 1 in 100,000 patient-years of exposure [18]. This is far lower than the ONJ risk associated with high-dose IV bisphosphonate therapy in oncology settings. A systematic review of 31 studies (N=71,549 patients) found that the ONJ incidence in oral bisphosphonate users was 0.001 to 0.01% per year [18]. The American Dental Association recommends that patients undergoing invasive dental procedures continue oral bisphosphonates for most elective extractions, though a case-by-case discussion with the treating dentist is appropriate for complex surgical cases [19].

Atypical subtrochanteric femur fractures (AFF) are a recognized but rare complication of prolonged bisphosphonate therapy. The risk increases with duration of use: the absolute risk is roughly 3.2, 50 per 100,000 patient-years and rises after five years of continuous therapy [20]. By contrast, hip fracture rates in untreated women with osteoporosis can reach 20, 30 per 1,000 patient-years, a risk more than 400 times larger than the AFF risk [20]. Any patient on long-term alendronate who reports new thigh or groin pain should have radiographs of the full femur to screen for cortical stress reactions.

Deprescribing Alendronate: When and How to Stop in Older Adults

The concept of a bisphosphonate drug holiday applies uniquely to this drug class because alendronate persists in bone for years after discontinuation, maintaining partial antiresorptive activity. After three to five years of oral alendronate therapy, clinicians should reassess whether continued treatment is warranted.

The American Society for Bone and Mineral Research (ASBMR) task force recommends the following approach. Patients at low-to-moderate fracture risk after three to five years of treatment may take a drug holiday of two to three years, during which BMD and FRAX are reassessed every two years. Patients with a femoral neck T-score below -2.5 at reassessment, a prior hip or vertebral fracture, or a high FRAX probability should continue treatment or switch to an alternative agent without a holiday [21].

In the FLEX trial (N=1,099), women who had completed five years of alendronate and then continued for an additional five years had 52% fewer clinical vertebral fractures compared with those who switched to placebo, but nonvertebral fracture rates did not differ significantly between groups [10]. These data support extending treatment to ten years in patients at high vertebral fracture risk, while allowing a holiday for lower-risk individuals.

For older adults in residential care or with multiple comorbidities, deprescribing discussions should incorporate life expectancy. Evidence suggests that the fracture-reduction benefit of bisphosphonates begins within 12 to 18 months of initiation and that patients with a life expectancy under one year are unlikely to experience net benefit. The FRAX tool does not adjust for life expectancy directly; clinical judgment must fill that gap [22].

Falls Risk, Cognitive Load, and Practical Prescribing Considerations

Alendronate itself does not cause sedation, orthostasis, or neuromuscular impairment, meaning it does not independently increase falls risk. This is clinically relevant because falls represent the proximate cause of most hip fractures in older adults [23]. The Beers Criteria (2023 update) do not list bisphosphonates as potentially inappropriate medications for older adults, distinguishing them from the many drug classes that do warrant caution in this population [24].

However, the administration protocol adds cognitive and physical demands. The patient must recall to take the tablet fasting, stay upright afterward, and avoid other morning medications for 30 minutes. For patients with mild cognitive impairment, a caregiver prompt or blister-pack reminder system may be necessary. Clinicians in memory care and assisted-living settings should document the monitoring plan in the medication administration record rather than relying on patient self-report.

Physical frailty independently raises fracture risk. A meta-analysis of 15 prospective cohort studies (N=36,826) found that frail older adults had a fracture incidence rate 1.7 times higher than non-frail peers after adjusting for BMD [25]. Prescribing alendronate in frail older adults is appropriate and generally well-supported by guidelines, but frailty assessment using a validated tool (Clinical Frailty Scale, FRAIL questionnaire) should inform the shared decision-making conversation about treatment goals.

Special Populations Within the Geriatric Group

Men with osteoporosis. Alendronate 10 mg daily or 70 mg weekly is FDA-approved for osteoporosis treatment in men. A two-year RCT (N=241 men, mean age 63) showed alendronate increased lumbar spine BMD by 7.1% versus 1.8% for placebo (P<0.001) [26]. Men are systematically undertreated for osteoporosis; only 14% of men with a fragility fracture receive pharmacotherapy within a year, compared with 31% of women, per a 2021 claims analysis published in JBMR [27].

Glucocorticoid-induced osteoporosis. Older adults on chronic prednisone face compounded bone loss. In a 48-week RCT (N=477), alendronate 10 mg daily increased lumbar spine BMD by 2.8% in glucocorticoid-treated patients versus a 0.6% loss in the placebo group (P<0.001) [28]. The ACR 2022 guideline recommends bisphosphonate initiation in this population, with preference for oral alendronate or risedronate in patients with adequate renal function and no GI contraindications [15].

Patients with prior fragility fracture. A hip or vertebral fragility fracture in an older adult is the single strongest predictor of subsequent fracture, and it should trigger pharmacotherapy without delay. A systematic review and meta-analysis in BMJ (2011) confirmed that bisphosphonate initiation within 90 days of hip fracture was associated with a 28% lower risk of subsequent fracture (RR 0.72 to 95% CI 0.62, 0.83) compared with delayed or no treatment [29].

Choosing Between Alendronate and Alternative Agents in Older Adults

Alendronate is a reasonable first-line choice for most geriatric patients with adequate renal function, no esophageal disease, and intact swallowing. When those conditions are not met, alternatives include zoledronic acid 5 mg IV once yearly, denosumab 60 mg SC every six months, or, in very high-risk patients, anabolic agents such as teriparatide 20 mcg SC daily or romosozumab 210 mg SC monthly for twelve months.

Zoledronic acid bypasses the GI tract entirely and removes the adherence problem associated with weekly oral dosing. The HORIZON Key Fracture Trial (N=7,765, mean age 73) showed that zoledronic acid reduced hip fractures by 41% and vertebral fractures by 70% over three years compared with placebo [30]. Renal monitoring is equally required: zoledronic acid is contraindicated at CrCl <35 mL/min and must be infused over no less than 15 minutes to reduce nephrotoxicity risk.

Denosumab 60 mg SC every six months does not require renal dose adjustment and is often preferred in patients with CKD stage 3, 4. The FREEDOM trial (N=7,868) showed a 68% reduction in vertebral fractures and 40% reduction in hip fractures over three years [31]. A critical caveat: discontinuation of denosumab without transition to a bisphosphonate is associated with rebound increases in bone turnover and multiple vertebral fractures, a risk that is particularly serious in older adults with pre-existing vertebral disease [32].

Alendronate 70 mg weekly costs approximately $15, 30 per month for the generic formulation, making it among the most cost-effective options for patients without specific contraindications.